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  D
isease mongering turns healthy 
people into patients, wastes 
precious resources, and causes 
iatrogenic harm. Like the marketing 
strategies that drive it, disease 
mongering poses a global challenge 
to those interested in public health, 
demanding in turn a global response. 
This theme issue of   PLoS Medicine   is 
explicitly designed to help provoke and 
inform that response. 
    What Is Disease Mongering? 
    The problem of disease mongering 
is attracting increasing attention 
[1–3], though an adequate working 
deﬁ  nition remains elusive. In our view, 
disease mongering is the selling of 
sickness that widens the boundaries 
of illness and grows the markets for 
those who sell and deliver treatments. 
It is exempliﬁ  ed most explicitly by 
many pharmaceutical industry–funded 
disease-awareness campaigns—more 
often designed to sell drugs than to 
illuminate or to inform or educate 
about the prevention of illness or 
the maintenance of health. In this 
theme issue and elsewhere, observers 
have described different forms 
of disease mongering: aspects of 
ordinary life, such as menopause, 
being medicalised; mild problems 
portrayed as serious illnesses, as 
has occurred in the drug-company-
sponsored promotion of irritable 
bowel syndrome (see pp. 156–174 in 
[2]; [4]) and risk factors, such as high 
cholesterol and osteoporosis, being 
framed as diseases.
    Drug companies are by no means the 
only players in this drama. Through 
the work of investigative journalists, we 
have learned how informal alliances 
of pharmaceutical corporations, 
public relations companies, doctors’ 
groups, and patient advocates 
promote these ideas to the public 
and policymakers—often using mass 
media to push a certain view of a 
particular health problem. While 
these different stakeholders may 
come to these alliances with different 
motives, there is often a conﬂ  uence of 
interests—resulting in health problems 
routinely being framed as widespread, 
severe, and treatable with pills, as 
has happened recently with social 
anxiety disorder [5]. Currently, these 
alliances are working with the media 
to popularize little-known conditions, 
such as restless legs syndrome [6] 
and female sexual dysfunction [7], in 
each case lending credence to inﬂ  ated 
prevalence estimates. In the case 
of female sexual dysfunction, there 
has been a serious, though heavily 
contested, attempt to convince the 
public in the United States that 43% of 
women live with this condition (see pp. 
175–195 in [2]). This is happening at a 
time when pharmaceutical companies 
perceive a need to build and maintain 
markets for their big-selling products 
and when pipelines for new and 
genuinely innovative medicines are 
perceived as being weak.
    A Context for Disease Mongering
    Three decades ago, Ivan Illich 
argued polemically that the medical 
establishment was “medicalising” 
life itself [8], and in the 1990s 
Lynn Payer described widening the 
boundaries of illness as “disease 
mongering” [3], highlighting the role 
of pharmaceutical companies. Today’s 
debate about this phenomenon, while 
still maturing, both acknowledges the 
axiomatic interest of corporations and 
professionals in maximizing turnover 
and appreciates that well-informed 
citizens may choose to embrace the 
medicalisation of health problems 
previously regarded as troublesome 
inconveniences. 
    It can also be argued that disease 
mongering is the opportunistic 
exploitation of both a widespread 
anxiety about frailty and a faith in 
scientiﬁ  c advance and “innovation”—
a powerful economic, scientiﬁ  c, 
and social norm. In many nations, 
government policy priority is to secure 
market-based economic development, 
while more equitable social policies, 
such as public health strategies, can 
become subordinate or redundant. 
Disease mongering can thrive in 
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such a normative environment. 
The practical consequences are 
that many of the so-called disease-
awareness campaigns that inform 
our contemporary understanding of 
illness—whether as citizens, journalists, 
health professionals, industry leaders, 
academics, or policymakers—are 
now underwritten by the marketing 
departments of large drug companies 
rather than by organizations with 
a primary interest in public health. 
And it is no secret that those same 
marketing departments contract 
advertising agencies with expertise 
in “condition branding,” whose skills 
include “fostering the creation” of new 
medical disorders and dysfunctions 
[9]. As a recent   Reuters Business Insight   
report on so-called lifestyle drugs— 
designed to be read by pharmaceutical 
industry leaders—pointed out, “The 
coming years will bear greater witness 
to the corporate sponsored creation 
of disease” [10]. We hope the coming 
years will also bear witness to a much 
more vigorous effort from within civil 
society to understand and to challenge 
that corporate process.
  Problems  Deﬁ  ning Disease 
Mongering 
    While the term “disease mongering” is 
now commonly used as shorthand to 
describe campaigns that inappropriately 
widen the boundaries of treatable 
illness, there is uncertainty about how 
to operationally deﬁ  ne the concept. 
With most disorders or conditions, 
there will be a number of individuals 
who suffer severe forms of the problem, 
who will beneﬁ  t greatly from treatment 
and may be helped enormously by the 
publicity and marketing given to both 
the treatment and the disorder. For 
example, industry-funded awareness 
raising about the treatment and 
prevention of HIV/AIDS has surely 
been valuable. But in other cases, the 
same marketing/awareness-raising 
campaign will be viewed very differently 
depending on the perspective of the 
observer: what an industry-linked 
professional group may consider to 
be legitimate public education about 
an underdiagnosed disease, an activist 
group free from industry sponsorship 
may regard as a crude attempt to build 
markets for potentially dangerous drugs.
    The Eli Lilly–sponsored promotion 
of premenstrual dysphoric disorder 
to help sell a re-branded version 
of ﬂ  uoxetine 
(rebranded from 
Prozac to Sarafem) 
is a case in point 
(see pp. 99–118 in 
[2]). Considered by 





by others as a 
condition that does 
not exist. 
    These discordant 
views of the same 
activity reinforce 
the fact that 
there are often 
different motives 
for the different 
individuals who 
get caught up in 
disease-mongering 
campaigns. In the 
pharmaceutical 
industry and in the 
public relations 
companies that 






and staff working in 
research or medical 
departments may 
express the same doubts as many 
working outside industry. For their 
part, the motives of health professionals 
and health advocacy groups may well be 
the welfare of patients, rather than any 
direct self-interested ﬁ  nancial beneﬁ  t, 
but we believe that too often marketers 
are able to crudely manipulate those 
motivations. Disentangling the 
different motivations of the different 
actors in disease mongering will be a 
key step towards a better understanding 
of this phenomenon. 
  Generating  Better  Knowledge 
    The views in this article are based 
on observations and interpretation 
informed by interviews with stakeholders 
and other more journalistic research 
methods, rather than a deeper 
academic investigation that employs 
qualitative and quantitative research 
techniques. Before embarking on 
research agendas to investigate disease 
mongering and its impacts, a broader 
conception of the phenomenon is 
warranted—requiring researchers to 
explore the uncertainty surrounding 
the deﬁ  nition of the problem, how and 
why different stakeholders understand 
it differently, and the deeper social and 
economic contexts. For example, the 
broad shift away from government-run 
programs and towards the marketplace 
within social democracies worldwide, 
and the consequent commercialisation 
and commodiﬁ  cation of health services, 
may be a useful framework for a more 
profound explanation of this problem. 
In a climate where governments are 
encouraging corporations to vigorously 
pursue for-proﬁ  t activities within the 
health-care sector, it is hardly surprising 
that pharmaceutical companies will 
use a range of promotional activities to 
widen the deﬁ  nitions of disease in order 
to grow the potential markets for their 
products. 
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    Along with deeper reﬂ  ection, we 
suggest researchers start to develop 
strategies for generating data on 
the impact of disease mongering. 
More conventional health-science 
methodologies may prove to be 
valuable ways of investigating the 
potential inﬂ  uences of a disease-
marketing campaign on outcomes such 
as public perceptions of a particular 
disease, prevalence/incidence rates for 
that disease, prescription patterns for 
the drugs linked to that disease, and 
even health status of those diagnosed 
with and/or treated for that disease. 
Multisite controlled studies of drug 
company–funded disease-awareness 
campaigns would be the ideal. 
However, deﬁ  ning appropriate control 
groups and devising indices to measure 
outcomes such as inappropriate 
medicalisation will prove extremely 
challenging since almost everyone is 
exposed to disease mongering in some 
form. Similarly, rigorous studies of 
publicly funded “counter-detailing”—
where noncommercially oriented 
information about disease is promoted 
to physicians and citizens—may be 
warranted, though, again, it is very 
difﬁ  cult methodologically. 
    Apart from these more challenging 
approaches, we believe there is a 
range of research projects that are 
both achievable and urgently needed. 
First, academic investigation of the 
prevalence of this problem would be 
highly desirable. Researchers could, 
for example, take a group of the most 
common (high-burden) diseases/
conditions, and investigate how and 
why the deﬁ  nitions of those diseases/
conditions have changed over time in 
different nations. Such retrospective 
investigations could include analysis of 
the decisions and recommendations 
of the panels that deﬁ  ne and re-
deﬁ  ne illness, the evidence informing 
those decisions, the conﬂ  icts of 
interest of panel members and their 
respective professional bodies, and 
the sponsorship of these processes. 
Early versions of this investigation are 
happening in a random, ad hoc way 
[11], but a coordinated systematic 
effort by a multinational group of 
respected researchers or research 
institutes is obviously preferable. As 
part of such an examination, a series of 
case studies would inevitably emerge, 
warranting deeper study and research 
and serving as a way to popularize 
awareness of the process of disease 
mongering. 
    Another potentially rich research 
method might involve a prospective 
study of the launch of a new or recently 
expanded disease or condition. 
A global collaboration could, for 
example, study the way female sexual 
dysfunction is being constructed and 
then promoted. “Creating the need” is 
now an established and integral part of 
the promotion of any new blockbuster 
drug, and sometimes that involves 
introducing a whole new condition 
to the wider public [12]. The success 
of sildenaﬁ  l depended on corporate-
funded disease-awareness campaigns 
promoting erectile dysfunction [13], 
and similarly the commercial success 
of any pharmaceutical treatments for 
female sexual dysfunction will hang 
in part on similar campaigns. While 
activists and scholars have begun the 
process of observing these activities, it 
is our view that the magnitude of public 
and private resources spent on these 
products, the potential harm that can 
ﬂ  ow from inappropriate medicalisation, 
and the opportunity cost in terms 
of treating and preventing genuine 
pathology demands more rigorous 
scientiﬁ  c investigation. 
  Time  for  Action?
    Around the world, there are tentative 
steps to identify, understand, and 
combat the threat to human health 
from the corporate-sponsored selling 
of sickness. These small steps are being 
taken by several players within the 
health ﬁ  eld, and we trust this theme 
issue may support and augment these 
developments.
    At a consumer level, Health Action 
International (http:⁄⁄www.haiweb.
org)—the activist group working for 
a more rational use of medicines 
globally—has for a long time been 
concerned about what it has described 
as the blurring of boundaries between 
ordinary life and medical illness in 
order to expand markets for drugs 
and other technologies [14]. Unlike 
many patient advocacy groups, Health 
Action International does not accept 
pharmaceutical company sponsorship, 
and actively warns others about the 
threats to independence from doing 
so [15]. By way of contrast, many 
consumer/advocacy groups around 
the world now rely on such funding 
[16], raising questions about their 
credibility, particularly as they are often 
used as the human face of disease-
awareness campaigns sponsored by 
their funders. An open debate within 
the health consumer movement about 
its close engagement with industry, and 
its involvement in disease mongering, 
would be welcome. 
    Likewise, amongst journalist circles, 
there are nascent debates about the 
media’s propensity to exaggerate 
disease prevalence and severity, and 
how to deal with this problem. In 
this issue of   PLoS Medicine  , two high-
proﬁ  le scholars with an interest in the 
area of medicine and the media, Lisa 
Schwartz and Steven Woloshin, present 
a timely and relevant case study on the 
“selling” of restless legs syndrome [6]. 
In Australia and Canada, a new media 
watch group called Media Doctor is 
also investigating the extent to which 
media stories on medicine either report 
appropriately on the nature and extent 
of illness or tend to simply regurgitate 
the promotional messages of disease-
mongering campaigns (http:⁄⁄www.
mediadoctor.org.au).
    While many professional 
organizations remain reliant on 
industry support, some are actively 
debating the problem of disease 
mongering. In a submission to the 
recent House of Commons inquiry into 
the inﬂ  uence of the pharmaceutical 
industry in Britain, the Royal College of 
General Practitioners outlined serious 
concerns about the process [17]. The 
subsequent report recommended that 
industry-funded disease-awareness 
campaigns should no longer be “veiled 
advertising” of branded drugs [18]. 
    Shareholders in the world’s large 
pharmaceutical companies have 
the strongest ﬁ  nancial interest in 
widening the boundaries of treatable 
illness in order to widen markets 
for their products. Yet in the debate 
about research and development for 
treatments for neglected diseases in the 
developing world, there are strong signs 
that shareholders can support policies 
driven by motivations other than proﬁ  t 
[19]. It may be that as key shareholders 
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and company executives alike 
understand more of the implications 
of what their marketing departments 
do, a challenge to the excesses of 
disease mongering may come from 
within industry, just as other parts of 
the health sector challenge excesses of 
disease mongering from within.
  Conclusion
    Genuine sustainable change, however, 
will not come until policymakers 
better understand the phenomenon of 
disease mongering and the potential 
beneﬁ  ts of responding against it. In 
Australia, for example, it has been 
estimated that winding back the public 
subsidy for inappropriate prescriptions 
of several high-proﬁ  le drugs to people 
with milder health problems could 
save hundreds of millions of dollars 
per year [20]. Those responsible for 
managing Australia’s publicly funded 
national formulary, the Pharmaceutical 
Beneﬁ  ts Scheme, have become 
increasingly concerned about what is 
described as “leakage”—the process 
where subsidised drugs are prescribed 
by physicians to people for whom 
use of the drug has been deemed 
not cost-effective because of a poor 
cost–beneﬁ  t ratio. We suspect that 
the estimated hundreds of millions 
of dollars of public money wasted on 
leakage in Australia annually is in part 
a result of drug companies promoting 
their products, through physicians, 
to people with mild problems for 
whom a powerful prescription may be 
unnecessary or even do more harm 
than good. In summary, combating 
disease mongering may improve the 
personal health of individuals, as well 
as the ﬁ  nancial health of public (and 
private) insurers.
    As an initial step toward combating 
disease mongering at a health policy 
level, we would urge decision makers 
to promote a renovation in the way 
diseases are deﬁ  ned. Continuing 
to leave these deﬁ  nitions to panels 
of self-interested specialists riddled 
with professional and commercial 
conﬂ  icts of interest is no longer viable. 
As a priority, new panels should be 
assembled, free of commercial conﬂ  icts 
of interest, involving a much wider, and 
less self-interested, group of players, 
who would ultimately generate more 
credible information. 
    Until a rigorous research agenda is 
initiated, and the social renovations 
and policy reforms that research might 
inform are enacted and evaluated, 
our beliefs, like those who argue for 
the beneﬁ  ts of corporate-sponsored 
disease-awareness campaigns, will 
remain based more on opinion than 
evidence. We hope this theme issue can 
start to change that.   
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